Bioceltix Enters into Grant Agreement for a Cell-Free Therapy Project for Dogs in Consortium with Jagiellonian University
Bioceltix S.A. has signed a grant agreement for the “InnoBioVet” project under the European Funds for a Modern Economy (FENG) programme. The project will be carried out in a consortium with researchers from Jagiellonian University. A Global Market Seeking New Solutions The veterinary healthcare market is growing rapidly, and spending on companion animal care continues […]
Bioceltix is getting closer to the registration of BCX‑CM‑J for osteoarthritis in dogs. The dialogue with the European Medicines Agency enters the next phase
Bioceltix has announced that it has submitted responses to the European Medicines Agency (EMA) regarding questions related to the BCX‑CM‑J product. This is one of the key elements of the registration process preceding the marketing authorisation of the drug. BCX‑CM‑J, developed by the Wrocław‑based biotech company, has the potential to become the world’s first veterinary […]
NCBR: Bioceltix project selected for funding in the amount of over PLN 15 million
It is estimated that as many as 15% of dogs suffer from atopic dermatitis. This is a chronic and very troublesome disease that significantly affects the quality of life of both animals and their caregivers. At Bioceltix, we are working on a solution that can genuinely help change this. Our project focused on developing a […]
We are in the TOP3 of the “Stock Exchange Company of the Year”
We made our debut in the “Stock Exchange Company of the Year” ranking a year ago. Yesterday, we once again stood on the podium, adding four more distinctions to our pool of awards. In the 27th edition of the Puls Biznesu ranking, we received the highest scores from analysts and fund managers in the “Growth […]
Results from long-term follow-up of patients in the BCX-CM-AD study on atopic dermatitis. Therapeutic effect observed even after 6 months
We have very good news for dog owners! We have completed the 168th day of patient follow-up after a single administration of BCX-CM-AD for atopic dermatitis. The conclusions? In nearly half of the patients who received BCX-CM-AD, the therapeutic effect is maintained for at least 6 months. This means that a single dose of our […]
Bioceltix Receives Environmental Approval for the Construction of a New Stem Cell Manufacturing Facility
The environmental decision issued by the Mayor of Wrocław marks a key milestone in the implementation of the most important investment in the history of the publicly listed company – the construction of a large-scale manufacturing facility for biological medicines for companion animals. The decision precedes Bioceltix’s application for a building permit for what is […]
Bioceltix’s share offering is a success. The company will raise nearly PLN 53 million to build a new stem cell facility.
Bioceltix will raise nearly PLN 53 million gross, among other things, for the construction of a plant for veterinary medicinal products containing stem cells, which is expected to be the largest of its kind in the world. This new, large-scale plant will provide Bioceltix with industrial-scale production of biologics that combat the most common diseases […]
Bioceltix SA shareholders have approved the share issue. The company plans to raise approximately PLN 45 million for the construction of a new stem cell facility.
Bioceltix, a publicly traded biotechnology company with a veterinary profile, received shareholder support for an issue of up to 457,000 shares during its Extraordinary General Meeting. The company plans to raise approximately PLN 45 million, which will allow it to complete the construction of a large-scale pharmaceutical production facility and secure its financial position for […]
Bioceltix S.A. plans to finance part of the costs of the ongoing construction of a pharmaceutical plant through the issue of shares
A publicly traded biotechnology company developing veterinary medicines for companion animals is working with contracted subcontractors to build a large-scale stem cell facility, which will be one of the largest of its kind in the world. The investment is covered by a conditional grant from the Polish Agency for Enterprise Development (PARP), which delays the […]
Bioceltix SA announces the success of a clinical trial of a product for atopic dermatitis in dogs. The company is one step closer to registering a breakthrough drug.
A veterinary biotech company listed on the Warsaw Stock Exchange (GPW) has published the final results of a clinical trial of BCX-CM-AD for atopic dermatitis (AD) in dogs. These confirm the safety and effectiveness of Bioceltix’s cell therapy in the short, medium, and long term. A single administration of the drug significantly alleviated skin lesions […]
Bioceltix is initiating the registration process for a drug for equine arthritis. The company has submitted an application to the European Medicines Agency.
Another important milestone in the history of Bioceltix. The publicly traded veterinary company has submitted an application to the European Medicines Agency (EMA) for a positive recommendation for the stem cell-based drug BCX-EM for equine arthritis. The excellent results from the product’s clinical trial confirmed its efficacy and safety. The drug’s therapeutic effect persists even […]
Bioceltix announces success in clinical trial of equine arthritis product. Company one step closer to registration and commercialization of breakthrough drug
A veterinary biotechnology company listed on the Warsaw Stock Exchange (GPW) has published the full results of a clinical trial of a product for equine arthritis. They confirm the efficacy and safety of the pioneering technology using mesenchymal stem cells. The results indicate that the therapeutic effect of a single dose of BCX-EM was achieved […]